Acura slides on data for abuse-deterrent Vicodin formulation

Acura Pharmaceuticals Inc. (NASDAQ:ACUR) fell $0.37 (20%) to $1.50 on Tuesday after its Vycavert missed the primary endpoint in the Phase II Study 301 to treat moderate to severe pain. Vycavert is an oral, immediate-release formulation of hydrocodone with acetaminophen that uses Acura's Aversion abuse-deterrent technology. In 40 recreational drug abusers in the trial, Vycavert did not lead to a lower mean maximum drug liking vs. generic hydrocodone/acetaminophen, which is known under the brand name Vicodin. The trial was designed to assess the abuse liability of snorting a crushed Vycavert tablet. ...